Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 294

1.

Interactions between triazoles and amphotericin B against Cryptococcus neoformans.

Barchiesi F, Schimizzi AM, Caselli F, Novelli A, Fallani S, Giannini D, Arzeni D, Di Cesare S, Di Francesco LF, Fortuna M, Giacometti A, Carle F, Mazzei T, Scalise G.

Antimicrob Agents Chemother. 2000 Sep;44(9):2435-41.

2.

Interactions of posaconazole and flucytosine against Cryptococcus neoformans.

Barchiesi F, Schimizzi AM, Najvar LK, Bocanegra R, Caselli F, Di Cesare S, Giannini D, Di Francesco LF, Giacometti A, Carle F, Scalise G, Graybill JR.

Antimicrob Agents Chemother. 2001 May;45(5):1355-9.

3.

Terbinafine inhibits Cryptococcus neoformans growth and modulates fungal morphology.

Guerra CR, Ishida K, Nucci M, Rozental S.

Mem Inst Oswaldo Cruz. 2012 Aug;107(5):582-90.

4.
5.

In vitro and in vivo efficacies of the azole SCH56592 against Cryptococcus neoformans.

Perfect JR, Cox GM, Dodge RK, Schell WA.

Antimicrob Agents Chemother. 1996 Aug;40(8):1910-3.

6.
7.

In vitro and in vivo antifungal activities of FX0685, a novel triazole antifungal agent with potent activity against fluconazole-resistant Candida albicans.

Takahata S, Okutomi T, Ohtsuka K, Hoshiko S, Uchida K, Yamaguchi H.

Med Mycol. 2005 May;43(3):227-33.

PMID:
16010849
8.

In-vitro interaction of terbinafine with amphotericin B, fluconazole and itraconazole against clinical isolates of Candida albicans.

Barchiesi F, Di Francesco LF, Compagnucci P, Arzeni D, Giacometti A, Scalise G.

J Antimicrob Chemother. 1998 Jan;41(1):59-65.

PMID:
9511038
9.

In vitro susceptibility studies of Cryptococcus neoformans isolated from patients with no clinical response to amphotericin B therapy.

Rodero L, Córdoba S, Cahn P, Hochenfellner F, Davel G, Canteros C, Kaufman S, Guelfand L.

J Antimicrob Chemother. 2000 Feb;45(2):239-42.

PMID:
10660509
10.
11.

Voriconazole, combined with amphotericin B, in the treatment for pulmonary cryptococcosis caused by C. neoformans (serotype A) in mice with severe combined immunodeficiency (SCID).

Silva EG, Paula CR, de Assis Baroni F, Gambale W.

Mycopathologia. 2012 Jun;173(5-6):445-9. doi: 10.1007/s11046-011-9499-2. Epub 2011 Nov 10.

PMID:
22071662
14.

Evaluation of antifungal combination against Cryptococcus spp.

Reichert-Lima F, Busso-Lopes AF, Lyra L, Peron IH, Taguchi H, Mikami Y, Kamei K, Moretti ML, Schreiber AZ.

Mycoses. 2016 Sep;59(9):585-93. doi: 10.1111/myc.12510. Epub 2016 May 2.

PMID:
27135278
15.

In vitro susceptibility of Candida dubliniensis to current and new antifungal agents.

Quindós G, Carrillo-Muñoz AJ, Arévalo MP, Salgado J, Alonso-Vargas R, Rodrigo JM, Ruesga MT, Valverde A, Pemán J, Cantón E, Martín-Mazuelos E, Pontón J.

Chemotherapy. 2000 Nov-Dec;46(6):395-401.

PMID:
11053905
17.

Additive potential of combination therapy against cryptococcosis employing a novel amphotericin B and fluconazole loaded dual delivery system.

Khan AA, Alanazi AM, Jabeen M, Khan S, Malik A.

Eur J Pharm Sci. 2018 Jul 1;119:171-178. doi: 10.1016/j.ejps.2018.04.015. Epub 2018 Apr 11.

PMID:
29653177
18.

Identification of a Cryptococcus neoformans cytochrome P450 lanosterol 14α-demethylase (Erg11) residue critical for differential susceptibility between fluconazole/voriconazole and itraconazole/posaconazole.

Sionov E, Chang YC, Garraffo HM, Dolan MA, Ghannoum MA, Kwon-Chung KJ.

Antimicrob Agents Chemother. 2012 Mar;56(3):1162-9. doi: 10.1128/AAC.05502-11. Epub 2011 Dec 12.

19.

Susceptibility testing of Cryptococcus diffluens against amphotericin B, flucytosine, fluconazole, itraconazole, voriconazole and posaconazole.

Kantarcioğlu AS, Boekhout T, Yücel A, Altas K.

Med Mycol. 2009 Mar;47(2):169-76. doi: 10.1080/13693780802213407. Epub 2008 Jul 24.

PMID:
18654925
20.

Supplemental Content

Support Center